When will the RCT-01 treatment for tendon repair be available on the market?

In short, we are not yet in a position to adequately predict this. RepliCel recently completed phase 1 human clinical trials of all its products currently in development, including RCT-01.

In most countries, it takes completing at least three phases of clinical trials to obtain approval to market a product. There are some exceptions to this general rule. For instance, Japan has created rules by which certain cell therapies may be commercially launched much faster than is the case in most countries.

We are working with our partners to explore opportunities to bring RCT-01 to market as soon as possible in certain countries. Stay tuned!